Gene Information
|
Gene Name
|
A33
|
|
Species
|
Human
|
|
Gene Length
|
960 bp
|
|
Product Feature
|
Full length Clone DNA of Homo sapiens glycoprotein A33 (transmembrane).
|
|
Sequence Signature
|
Identical with the Gene Bank Ref. ID sequence (Nucleotide may contain silent mutation without changing amino acid sequence)
|
Plasmid Information
|
Vector
|
pLV-C-GFPSpark®
|
|
Promoter
|
Enhanced CMV mammalian cell promoter
|
|
Tag Sequence
|
GFPSpark Tag Sequence: GTGAGCAAGGGC……GAGCTGTACAAG
|
|
Sequencing Primer
|
pLen-F(CTCGTTTAGTGAACCGTCAGAATT), pLen-R(GAACCGGAACCCTTAAACATGT)
|
|
Quality Control
|
The plasmid is confirmed by full-length sequencing.
|
|
Bacterial Screening Resistance
|
Ampicillin
|
Background
Cell surface A33 antigen, also known as glycoprotein A33, is a single-pass type I membrane protein that is expressed in the normal gastrointestinal epithelium and 95% of colon cancers. GPA33 contains one Ig-like C2-type (immunoglobulin-like) domain and one Ig-like V-type (immunoglobulin-like) domain. The open reading frame encodes a 319-amino acid polypeptide having a putative secretory signal sequence and 3 potential glycosylation sites. The predicted mature protein has a 213-amino acid extracellular region, a single transmembrane domain, and a 62-amino acid intracellular tail. Intracellular traffic and recycling to the cell surface appear to play a major role in GPA33 function and to have an influence on its surface density superseding translational regulation. GPA33 has become a promising target of immunologic therapy strategies, but its biologic function and potential role in tumorigenesis are unknown. EpCAM protein and GPA33 mRNA expressions are specific and sensitive markers of Barrett's metaplasia (BM). GPA33 may also play a role in cell-cell recognition and signaling.
Cancer Immunotherapy
Immune Checkpoint
Immunotherapy
Targeted Therapy
![A33 Lentiviral cDNA ORF Clone, Human, C-GFPSpark® tag [BY-Q-10235]](http://30712400.s21i.faiusr.com/4/1/ABUIABAEGAAgy_O3ogYo6vHDkwQwmwQ46AU!400x400.png)
